Interní Med. 2010; 12(11): 540-544

Hirsutism-not only cosmetic problem

MUDr.Jana Heresová, CSc.1, MUDr.Marie Vrzáňová2
1 Klinika nukleární medicíny a endokrinologie 2. LF UK a FN Motol, Praha
2 Interní klinika 2. LF UK a FN Motol, Praha

Androgenic disorders have many negative physical effects. These effects may be caused by excess androgen (exogenous or endogenous)

or by end-organ sensitivity to normal levels of androgens. The most apparent signs of androgen excess are the external manifestations,

including: oily skin, acne, hirsutism, android obesity, and androgenic alopecia. Of equal concern are the potential metabolic disturbances

associated with hyperandrogenicity. Hirsutism is pathologic growth and distribution of hair in women in response to androgen

stimulation of pilosebaceous unit. Incidence in women is about 5–10 %. Hyperandrogenism must be considered in any girl with premature

pubarche. An association with menstrual irregularity or obesity in a teenage girl is the most common causes of functional ovarian

hyperandrogenism, one manifestation of which is polycystic ovary syndrome, and functional adrenal hyperandrogenism, which usually

seems to be due to an exaggeration of adrenarche. The plasma testosterone/free testosterone is a more sensitive indicator of hyperandrogenism.

Optimal therapeutic program is designed for many patients, including oral contraceptives, low-dose glucocorticoids, and

antiandrogens. Treatment should be chosen according to the patient‘s symptoms and source of androgens and should be combined

with traditional therapy for the specific dermatologic and cosmetologic disorder.

Keywords: hirsutism, androgens, enzym, therapy

Published: December 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Heresová J, Vrzáňová M. Hirsutism-not only cosmetic problem. Interní Med. 2010;12(11):540-544.
Download citation

References

  1. Garn SM. Types and distribution of the hair in men. Ann. NY. Acad. Sci 1951; 53: 498-507. Go to original source... Go to PubMed...
  2. Muller SA. Hirsutism. Am. J. Med. 1969; 46: 803-817. Go to original source... Go to PubMed...
  3. Ferriman D, Gallwey JD. Clinical Assessment of body hair growth in women. J. Clin. Endocr. Metab. 1961; 21: 1440. Go to original source... Go to PubMed...
  4. Cibula D, Stárka L, Vrbíková J, a kol. Syndrom polycystických ovarií. Jessenius - Maxdorf, Praha, 2004; 110.
  5. Stárka L, a kol. Aktuální endokrinologie. Maxdorf Jessenius, Praha, 1999: s. 721.
  6. Stárka L, a kol. Pokroky v endokrinologii. Maxdorf Jessenius, Praha, 2007: s. 736.
  7. Spritzer PM, Lisboa S, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin. Endocr. 2000; 52: 587-594. Go to original source... Go to PubMed...
  8. Stárka L, a kol. Endokrinologie, Triton. Praha 2010: s. 220.
  9. Fait T, a kol. Estrogenní deficit. Maxdorf Jessenius, Praha, 2007: s. 276.
  10. Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric. 2003; 6(suppl 3): 49-54. Go to PubMed...
  11. Schindler E. Antiandrogenic progestins for signs of androgenisation and hormonal contraception. Eur. J. Obst. Gynecol. Repr. Biol. 2004; 112(2): 136-141. Go to original source... Go to PubMed...
  12. Líbalová Z. Kontraceptiva. Moderní gynekologie a porodnictví 2003; 12(3): 415-426.
  13. Fait T. Klimakterická medicína. Jessenius-Maxdorf, Praha, 2006: s. 103.
  14. Rulcová J. Kombinovaná orální kontraceptiva s pozitivním vlivem na pleť z dermatologického hlediska. Klin. Farmakol. Farm. 2005; 19: 225-228.
  15. Van der Spuy ZM, Le Roux PA. Cyproterone acetate for hirsutism. Cochrane database Syst. Rev. 2003 (4): CD001125. Go to original source...
  16. Bayram F. Muderris I, Guven M, et al. Low-dose (2,5 mg/ day) finasteride treatment in hirsutism. Gynecol. Endocrinol. 2003; 17(5): 419-422. Go to original source... Go to PubMed...
  17. Falsetti L, Gambera A, Legrenzi L, et al. Comparison of finasterid versus flutamide in the treatment of hirsutism. Europ. J. Endocr. 1999; 141: 361-367. Go to original source... Go to PubMed...
  18. Hoffmann R. A 4-month, open-label study evaluating the efficacy of eflornithine 11.5 % cream in the treatment of unwanted facial hair in women using TrichoScan. Eur J Dermatos. 2008; 18(1): 65-70.
  19. Frank-Raue K, Junga G, Vescei P, Ziegler R. Therapy of hirsutism in females with adrenal enzyme defects of streoid hormone biosynthesis: comparison of dexamethasone with cyproterone acetate. Klin. Wochenschr. 1990; 68(12): 597-601. Go to original source... Go to PubMed...
  20. Rosenfield RL. Hirsutism and variable response of the pilosebaceous units on androgen. J. Invest. Dermatol. Symp. Proc. 2005; 10(3): 205-208. Go to original source... Go to PubMed...
  21. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999; 341: 709-717. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.